Cargando…
Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective
Over the last decade, clinical trials using various poly ADP ribose polymerase (PARP) inhibitors on patients with ovarian cancer have shown promising results. The introduction of PARP inhibitors has changed the treatment landscape and improved outcomes for patients with ovarian cancer. Fuzuloparib,...
Autores principales: | Li, Ning, Liu, Qi, Tian, Yu, Wu, Lingying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634097/ https://www.ncbi.nlm.nih.gov/pubmed/36335989 http://dx.doi.org/10.3802/jgo.2022.33.e86 |
Ejemplares similares
-
Fuzuloparib: First Approval
por: Lee, Arnold
Publicado: (2021) -
Correction to: Fuzuloparib: First Approval
por: Lee, Arnold
Publicado: (2021) -
Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer
por: Wu, Yawen, et al.
Publicado: (2022) -
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
por: Liu, Yaxin, et al.
Publicado: (2023) -
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
por: Borella, Fulvio, et al.
Publicado: (2020)